

Press Release

Jambuwala Pharmaceuticals Limited

November 19, 2019

Rating Reaffirmed



Total Bank Facilities Rated*	Rs. 10.00 Cr.
Long Term Rating	ACUITE B / Outlook: Stable

* Refer Annexure for details

Rating Rationale

Acuite has reaffirmed long-term rating of '**ACUITE B**' (read as **ACUITE B**) to the Rs.10.00 crore bank facilities of JAMBUWALA PHARMACEUTICALS LIMITED. The outlook is '**Stable**'.

Jambuwala Pharmaceuticals Limited (JPL), based at Ahmedabad (Gujarat), was incorporated in 2017. The company will be engaged in manufacturing, trading of generic and general medicines in pharmaceutical industry made for human consumption. The manufacturing facility is located at Sanand (Ahmedabad) with installed capacity of 18000 lakhs of Tablets and 1800 lakhs of Capsules per annum.

Analytical Approach

Acuite has considered the standalone business and financial risk profiles of JPL to arrive at this rating.

Key Rating Drivers

Strengths

• Experienced management

The key promoters, Mr. Pranlal Bhailal Shah and Mr. Hiren Vijaykumar Doshi possess more than three decades of experience in the commodities, broking and pharmaceutical industry. Other promoters, Mr. Kamal Shah and Mr. Chintan Pranlal Shah possess a decade of experience in the commodity trading and brokerage business through their association with other companies in Jambuwala Group. The rich experience and expertise of promoters in the same line of business will ensure timely execution of project. Currently, the company is into trading of pharmaceuticals and expects manufacturing.

Acuite believes that JPL will benefit from experienced management which will help the firm to maintain long standing relations with its customers and suppliers.

Weaknesses

• Project offtake risk

The commercial operations are expected to commence from February, 2020, while it was expected to start in April, 2019 due to delay in construction. Thus, the project faces off-take risk. Delay in project commencement has led to cost overrun from total project cost of Rs.14.91 crore to ~Rs.20.00 crore. The project is being funded by Rs.5.75 crore of Term Loan, Rs.2.00 crore of working capital and rest from promoter's contribution in form of equity and unsecured loan.

However, the same is mitigated to some extent as the project is 90.00 percent completed and extensive promoters' experience will help timely execution.

• Intense competition and regulatory risk

The company operates in pharmaceutical, generic and general medicine sector, which is marked by the presence of large number of players which will put pressure on margins and restricts bargaining power with the clients. Further, the industry is highly regulated by the regulatory board and requires many licenses. Any change in regulation or government policy will have adverse impact on business of the company.

Rating Sensitivities

- Substantial reduction in GCA days to around 70-90 days.
- Stretch in working capital cycle leading to increase in working capital borrowings.

Material Covenants

None

Liquidity position: Stretched

Acuite expects that the liquidity position of JPL will be stretched for the first year of operations. Acuite believes that the promoters would support the company till operations stabilise. The liquidity of the company is likely to remain stretched over the medium term on account of nascent stage of operations and will rely on the ability of the promoters to fund the liquidity deficit in the initial stage of operations.

Outlook: Stable

Acuite believes that JPL will maintain 'Stable' business risk profile over the medium term on account of the management's experience in the pharmaceutical industry. The outlook may be revised to 'Positive' if the company achieves its projected scale of operations and profitability. Conversely, the outlook may be revised to 'Negative' in case of delays in project implementation.

About the Rated Entity - Key Financials

	Unit	FY19 (Actual)	FY18 (Actual)	FY17 (Actual)
Operating Income	Rs. Cr.	0.20	0.11	NA
EBITDA	Rs. Cr.	0.05	0.01	NA
PAT	Rs. Cr.	0.02	(0.00)	NA
EBITDA Margin	(%)	22.81	11.31	NA
PAT Margin	(%)	10.63	(1.52)	NA
ROCE	(%)	0.61	(0.06)	NA
Total Debt/Tangible Net Worth	Times	0.17	0.23	NA
PBDIT/Interest	Times	1,458.07	176.05	NA
Total Debt/PBDIT	Times	21.59	38.49	NA
Gross Current Assets (Days)	Days	2,321	803	NA

Status of non-cooperation with previous CRA (if applicable)

Not Applicable

Any other information

Acuite is yet to receive the latest No Default Statement (NDS) from the rated entity, despite repeated requests and follow-ups.

Applicable Criteria

- Default Recognition - <https://www.acuite.in/view-rating-criteria-17.htm>
- Trading Entities - <https://www.acuite.in/view-rating-criteria-61.htm>
- Financial Ratios and Adjustments - <https://www.acuite.in/view-rating-criteria-20.htm>

Note on complexity levels of the rated instrument

<https://www.acuite.in/criteria-complexity-levels.htm>

Rating History (Upto last three years)

Date	Name of Instrument / Facilities	Term	Amount (Rs. Cr.)	Ratings/Outlook
29-Nov-2019	Proposed Cash Credit	Long Term	2.00	ACUITE B /Stable (Assigned)
	Proposed Term Loan	Long Term	6.00	ACUITE B /Stable (Assigned)
	Proposed Long Term Loan	Long Term	2.00	ACUITE B /Stable (Assigned)

*Annexure – Details of instruments rated

Name of the Facilities	Date of Issuance	Coupon Rate	Maturity Date	Size of the Issue (Rs. Cr.)	Ratings/Outlook
Term Loan	Not Applicable	Not Applicable	Not Applicable	5.75	ACUITE B /Stable (Reaffirmed)
Cash Credit	Not Applicable	Not Applicable	Not Applicable	2.00	ACUITE B /Stable (Reaffirmed)
Proposed Long Term Loan	Not Applicable	Not Applicable	Not Applicable	2.25	ACUITE B /Stable (Reaffirmed)

Contacts

Analytical	Rating Desk
Aditya Gupta Head - Corporate and Infrastructure Sector Ratings Tel: 022-49294041 aditya.gupta@acuite.in Grishma Muni Analyst - Rating Operations Tel: 022-49294035 grishma.muni@acuite.in	Varsha Bist Manager - Rating Desk Tel: 022-49294011 rating.desk@acuite.in

About Acuite Ratings & Research:

Acuite Ratings & Research Limited (erstwhile SMERA Ratings Limited) is a full-service Credit Rating Agency registered with the Securities and Exchange Board of India (SEBI). The company received RBI Accreditation as an External Credit Assessment Institution (ECAI), for Bank Loan Ratings under BASEL-II norms in the year 2012. Since then, it has assigned more than 6,000 credit ratings to various securities, debt instruments and bank facilities of entities spread across the country and across a wide cross section of industries. It has its Registered and Head Office in Mumbai.

Disclaimer: An Acuite rating does not constitute an audit of the rated entity and should not be treated as a recommendation or opinion that is intended to substitute for a financial adviser's or investor's independent assessment of whether to buy, sell or hold any security. Acuite ratings are based on the data and information provided by the issuer and obtained from other reliable sources. Although reasonable care has been taken to ensure that the data and information is true, Acuite, in particular, makes no representation or warranty, expressed or implied with respect to the adequacy, accuracy or completeness of the information relied upon. Acuite is not responsible for any errors or omissions and especially states that it has no financial liability whatsoever for any direct, indirect or consequential loss of any kind arising from the use of its ratings. Acuite ratings are subject to a process of surveillance which may lead to a revision in ratings as and when the circumstances so warrant. Please visit our website (www.acuite.in) for the latest information on any instrument rated by Acuite.